Table 3 |
||||||
|
Cox regression analysis for breast cancer death for patients with gene expression data (n = 69 to 77) |
||||||
|
Univariate analysis |
Multivariate analysis |
|||||
|
|
|
|||||
|
RR |
95 percent CI |
P |
RR |
95 percent CI |
P |
|
|
|
||||||
|
Age, ≥55 years versus <55 years |
1.22 |
0.52–2.84 |
0.65 |
|||
|
Tumor type (overall effect) |
0.32 |
|||||
|
Lobular (versus ductal) |
0.65 |
0.28–1.51 |
0.31 |
|||
|
Other (versus ductal) |
0.34 |
0.05–2.53 |
0.29 |
|||
|
Tumor size (overall effect) |
0.014 |
|||||
|
pT2 (versus pT1) |
2.63 |
0.88–7.86 |
0.085 |
|||
|
pT3–pT4 (versus pT1) |
5.27 |
1.61–17.2 |
0.006 |
|||
|
Lymph node status (overall effect) |
0.016 |
0.004 |
||||
|
pN1 (versus pN0) |
0.45 |
0.16–1.26 |
0.13 |
0.47 |
0.17–1.33 |
0.15 |
|
pN2–pN3 (versus pN0) |
2.41 |
0.95–6.08 |
0.064 |
3.42 |
1.29–9.05 |
0.013 |
|
Othera (versus pN0) |
2.12 |
0.75–5.98 |
0.16 |
2.70 |
0.93–7.78 |
0.067 |
|
Histological grade (overall effect) |
0.68 |
|||||
|
G2 (versus G1) |
2.20 |
0.30–16.3 |
0.44 |
|||
|
G3 (versus G1) |
2.07 |
0.25–16.8 |
0.50 |
|||
|
TP53 mutation (versus wild type) |
3.46 |
1.66–7.21 |
0.002 |
4.43 |
2.04–9.64 |
0.0004 |
|
ER positive (versus negative) |
0.75 |
0.35–1.63 |
0.48 |
|||
|
PR positive (versus negative) |
0.71 |
0.33–1.51 |
0.38 |
|||
|
Gene expression (overall effect) |
0.006 |
|||||
|
Highly proliferating luminal (versus luminal A) |
6.59 |
1.79–24.3 |
0.005 |
|||
|
Normal like (versus luminal A) |
2.82 |
0.71–11.3 |
0.14 |
|||
|
Basal like (versus luminal A) |
6.93 |
1.79–26.8 |
0.005 |
|||
|
ERRB2+ (versus luminal A) |
5.82 |
1.30–26.2 |
0.022 |
|||
|
|
||||||
|
aLymph nodes not removed. 95 percent CI, 95 percent confidence interval for relative risk; ER, estrogen receptor; PR, progesterone receptor; P, P value for the hypothesis of no effect; RR, relative risk (hazard ratio). |
||||||
|
Langerød et al. Breast Cancer Research 2007 9:R30 doi:10.1186/bcr1675 |
||||||
